Global Aldose Reductase Inhibitor Market, By Site of Action (Neural Tissue, Retina, Kidney, Cardiovascular, Others), Drugs (Carboxylic Acid Derivatives, Spirohydantoins & Cyclic Amide, Phenolic Derivatives, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Aldose Reductase Inhibitor Market Analysis and Size
Increasing cases of diabetes boosts the aldose reductase inhibitor market. Diabetes mellitus incidence has been related to the huge modification of the physiological levels of glucose and is often associated with numerous long-term complications, such as nephropathy, retinopathy, neuropathy, cataract, and cardiovascular. Increasing adaptation of unhealthy lifestyle and rising metabolic and generic disorders, which increases the risk of emerging diabetes, also boosts up the aldose reductase inhibitor market growth.
Data Bridge Market Research analyses a growth rate in the aldose reductase inhibitor market in the forecast period 2023-2030. The expected CAGR of aldose reductase inhibitor market is tend to be around 6% in the mentioned forecast period. The market was valued at USD 6.71 billion in 2022, and it would grow upto USD 10.7 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Aldose Reductase Inhibitor Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Site of Action (Neural Tissue, Retina, Kidney, Cardiovascular, Others), Drugs (Carboxylic Acid Derivatives, Spirohydantoins & Cyclic Amide, Phenolic Derivatives, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
YZJ Group (China), Therapeutic Vision, Inc (India), Pierre Fabre Group (France) |
|
Market Opportunities |
|
Market Definition
Aldose reductase is an aldo-keto reductase super family enzyme catalyzes the conversion of glucose to sorbitol in polyol pathways of glucose metabolism. Contrastingly, the aldose reductase inhibitor declines the flux of sorbitol through polyol pathways. This inhibitor developed vary structurally, and representative structural classes which includes carboxylic acid derivatives such as Epalrestat, Alrestatin, Zopalrestat, Zenarestat, Ponalrestat, Lidorestat, and Tolrestat, then spirohydantoins and related cyclic amides and lastly phenolic derivatives
Aldose Reductase Inhibitor Market Dynamics
Drivers
- Increasing Incidence of Peripheral Neuropathy
Peripheral neuropathy is a very common complication of diabetes mellitus. Records of the incidence of neuropathy in people suffering from diabetes vary from 10 to 50%, depending on several factors such as how neuropathy is defined, methods of detection, and the population studied. A latest review states that neuropathy is available in around 30% of people attending hospital diabetes clinics, 20% of people with diabetes in primary care settings and 10% of the entire population of patients with diabetes. Furthermore, longitudinal studies of people with diabetic polyneuropathy have showed that their clinical and electrophysiological abnormalities degrade with time, although slowly. The trials used various measures to look for a benefit of treatment with aldose reductase inhibitors. Therefore, this factor boosts the market growth.
Opportunities
- Increasing Incidence of Foot Ulcers
The global incidence of foot ulcers in all people with diabetes is around 1%, but in those with known sensory loss from neuropathy, the occurrence is seven times higher. Furthermore, non‐healing foot ulcers follow the large majority of amputations in people suffering from diabetes, and diabetic polyneuropathy is related with a 2 to 25 fold increase in the risk of amputation. Thus, this rising prevalence of foot ulcers is surely boosting the growth of the market.
- Growing Demand for Retail Pharmacies
The rise in the number of aldose reductase inhibitor being supplied through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients favour retail pharmacies for purchasing drugs, as these are easily available and accessible.
Restraints/Challenges
- Side Effect of Treatment
There are adverse effects that are visible in patients with these inhibitors, except for extreme allergic reactions with sorbinil, impaired kidney function with zenarestat, and alteration of liver function with tolrestat. Thus, these restrain the market growth.
- High Cost of Treatment
The growing expenditure associated with the medications impede the market growth. These inhibitors cost high and people in the underdeveloped countries, which result in the under treatment of several patients. This hinders the market growth.
This aldose reductase inhibitor market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the aldose reductase inhibitor market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Aldose Reductase Inhibitor Market Scope
The aldose reductase inhibitor market is segmented on the basis of site of action, drug, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Site of Action
- Neural Tissue
- Retina
- Kidney
- Cardiovascular
- Others
Drug
- Carboxylic Acid Derivatives
- Spirohydantoins and Cyclic Amide
- Phenolic Derivatives
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Aldose Reductase Inhibitor Market Regional Analysis/Insights
The aldose reductase inhibitor market is analyzed and market size insights and trends are provided by site of action, drug, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the aldose reductase inhibitor market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for aldose reductase inhibitor market throughout the forecasted period because of the growing healthcare and R&D expenditure, patient awareness and major market players on novel technology or formulation of existing drugs plays major role for the growth of aldose reductase inhibitor market. Furthermore, Europe is considered to witness huge growth prospects in the upcoming years by increasing the expenditure on the healthcare sector.
Asia-Pacific dominates the market because of the high occurrence cases of diabetes and related disorders and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Aldose Reductase Inhibitor Market Share Analysis
The aldose reductase inhibitor market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to aldose reductase inhibitor market.
Key players operating in the aldose reductase inhibitor market include:
- YZJ Group (China)
- Therapeutic Vision, Inc (India)
- Pierre Fabre Group (France)
SKU-
